
SCANDION ONC 
 Share · DK0061031895   · A2N9BV  (XSTO)
                    No Price
                
            n/a
        
        Company Profile for SCANDION ONC Share
    
 Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of chemotherapy resistance. Its lead product candidate includes the SCO-101, an oral compound that is in clinical Phase Ib and Phase II studies in cancer patients. The company's other product candidate is SCO-201, which is in preclinical trial for the treatment of solid tumors. Scandion Oncology A/S was founded in 2017 and is headquartered in Copenhagen, Denmark.
 Company Data
Name SCANDION ONC
 Company Scandion Oncology A/S
  Website 
                            https://www.scandiononcology.com
                        
 Primary Exchange  NASDAQ STOCKHOLM AB
                        NASDAQ STOCKHOLM AB
                    
 WKN A2N9BV
 ISIN DK0061031895
 Asset Class Share
     Sector Healthcare
 Industry Biotechnology
 CEO Francois Regis Martelet
  Country Denmark
 Currency EUR
 Employees 0,0 T
 Address Symbion, 2100 Copenhagen
 IPO Date 2018-11-08
Ticker Symbols
| Name | Symbol | 
|---|---|
| NASDAQ STOCKHOLM AB | SCOL.ST | 
| Frankfurt | 8VY.F | 
            More Shares
            
 
                Investors who hold SCANDION ONC also have the following shares in their portfolio:
            
            The financial platform MoneyPeak tracks and analyzes investments and portfolios.
 From securities portfolios to crypto purchases.
            
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
 Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.



